Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein

Vaccine

Volumn 17, Issue 22, 1999, Pages 2862-2872

  Liang, Xiaoping ^a   Munshi, Sonal ^a   Shendure, Jay ^a   Mark III, George ^a   Davies, Mary E ^a   Freed, Daniel C ^a   Montefiori, David C ^b   Shiver, John W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HIV 1 Env protein; HIV 1 vaccine; mAb2F5

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; EXPRESSION VECTOR; GENE INSERTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELL LINE; EPITOPES; FEMALE; GUINEA PIGS; HIV ENVELOPE PROTEIN GP120; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; NEUTRALIZATION TESTS; VACCINES, SYNTHETIC;

EID: 0033575483     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00125-5     Document Type: Article

References (34)

1. Shiver J.W., Davies M.E., Yasutomi Y., Perry H.C., Freed D.C., Letvin N.L., Liu M.A. Anti-HIV env immunities elicited by nucleic acid vaccines. Vaccine. 15:1997;884-887.
2. McElrath M.J., Siliciano R.F., Weinhold K.J. HIV type 1 vaccine-induced cytotoxic T-cell responses in phase I clinical trials: Detection, characterization, and quantitation. AIDS Res Hum Retroviruses. 13:1997;211-216.
3. Letvin N.L., Montefiori D.C., Yasutomi Y., Perry H.C., Davies M.E., Lekutis C., Alroy M., Freed D.C., Lord C.I., Handt L.K., Liu M.A., Shiver J.W. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA pins protein vaccination. Proc Natl Acad Sci USA. 94:1997;9378-9383.
4. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandstrom E., Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 35:1998;1320-1325.
5. McElrath M.J., Corey L., Greenberg P.D., Matthews T.J., Montefiori D.C., Rowen L., Hood L., Mullins J.I. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc Natl Acad Sci USA. 93:1996;0027-8424.
6. Connor R.I., Korber B.T.M., Graham B.S., Hahn B.H., Ho D.D., Walker B.D., Neumann A.U., Vermund S.H., Mestecky J., Jackson S., Fenamore E., Cao Y., Gao F., Kalams S., Kunstman K.J., McDonald D., McWilliams N., Trkola A., Moore J.P., Wolinsky S.M. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol. 72:1998;1552-1576.
7. Weber J. MRC- V-001 study: a comparative trial of RGP120 with novel adjuvants. Girard M., Dodet B. Onzieme colloque des cent gardes: retroviruses of human AIDS and related animal diseases, 27-29 October, Narmes-la-Coquette, Paris, France. 1997.
8. Cao Y., Qin L., Zhang L., Safrit J., Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 332:1995;201-208.
9. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L., Hendry R.M., Dunlop N., Nara P.L., Lamacchia M., Garratty E., Stiehm E.R., Bryson Y.J., Cao Y., Moore J.P., Ho D.D., Barbas C.F. III. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266:1994;1024-1027.
10. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., Palese P., Katinger H. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol. 68:1994;4031-4034.
11. Conley A.J., Kessler J.A.n., Boots L.J., Tung J.S., Arnold B.A., Keller P.M., Shaw A.R., Emini E.A. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA. 91:1994;3348-3352.
12. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas C.F.r., Burton D.R., Ho D.D., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol. 69:1995;6609-6617.
13. Kessler J.A., McKenna P.M., Emini E.A., Chan C.P., Patel M.D., Gupta S.K., Mark G.E., Barbas C.F., Burton D.R., Conley A.J. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses. 13:1997;575-582.
14. Gauduin M.C., Parren P., Weir R., Barbas C.F., Burton D.R., Koup R.A. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med. 3:1997;1389-1393.
15. Conley A.J., Kessler J.A. II, Boots L.J., McKenna P.M., Schleif W.A., Emini E.A., Mark G.E. III, Katinger H., Cobb E.K., Lunceford S.M., Rouse S.R., Murthy K.K. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol. 70:1996;6751-6758.
16. Steimer K.S., Haigwood N.L. Importance of conformation on the neutralizing antibody response to HIV-1 gp120. Biotechnol Ther. 2:1991;63-89.
17. Reitter J.N., Means R.E., Desrosiers R.C. A role for carbohydrates in immune evasion in AIDS. Nat Med. 4:1998;679-684.
18. Garrity R.R., Rimmelzwaan G., Minassian A., Tsai W.P., Lin G., de Jong J.J., Goudsmit J., Nara P.L. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol. 159:1997;279-289.
19. Lu S., Wyatt R., Richmond J.F.L., Mustafa F., Wang S.X., Weng J.Y., Montefiori D.C., Sodroski J., Robinson H.L. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions: short communication. AIDS Res Hum Retroviruses. 14:1998;151-155.
20. Earl P.L., Broder C.C., Doms R.W., Moss B. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol. 71:1997;2674-2684.
21. Richardson T.M., Stryjewski B.L., Broder C.C., Hoxie J.A., Mascola J.R., Earl P.L., Doms R.W. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol. 70:1996;753-762.
22. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 67:1993;6642-6647.
23. Graham F.L., Smiley J. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 36:1977;59-72.
24. Graham F.L., Eb A.J.v.d. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 52:1973;456-467.
25. Kowalski J., Gilbert S.A., Van Drunen Littel Van Den Hurk S., Van Den Hurk J., Babiuk L.A., Zamb T.J. Heat-shock promoter-driven synthesis of secreted bovine herpesvirus glycoproteins in transfected cells. Vaccine. 11:1993;1100-1107.
26. Montefiori D.C., Robinson W.E. Jr, Schuffinan S.S., Mitchell W.M. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol. 26:1988;231-235.
27. Barbas C.F.r., Hu D., Dunlop N., Sawyer L., Cababa D., Hendry R.M., Nara P.L., Burton D.R. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci USA. 91:1994;3809-3813.
28. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., Cheng Mayer C., Robinson J., Maddon P.J., Moore J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature. 384:1996;184-187.
29. Gorny M.K., Xu J.Y., Karwowska S., Buchbinder A., Zolla Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol. 150:1993;635-643.
30. Moore J.P., Cao Y., Qing L., Sattentau Q.J., Pyati J., Koduri R., Robinson J., Barbas C.F.r., Burton D.R., Ho D.D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol. 69:1995;101-109.
31. Li A., Baba T.W., Sodroski J., ZollaPazner S., Gorny M.K., Robinson J., Posner M.R., Katinger H., Barbas C.F., Burton D.R., Chou T.C., Ruprecht R.M. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human Anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses. 13:1997;647-656.
32. Li A., Katinger H., Posner M.R., Cavacini L., ZollaPazner S., Gorny M.K., Sodroski J., Chou T.C., Baba T.W., Ruprecht R.M. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu(+) by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J Virol. 72:1998;3235-3240.
33. Mascola J.R., Louder M.K., VanCott T.C., Sapan C.V., Lambert J.S., Muenz L.R., Bunow B., Birx D.L., Robb M.L. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol. 71:1997;7198-7206.
34. Eckhart L., Raffelsberger W., Ferko B., Klima A., Purtscher M., Katinger H., Ruker F. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J Gen Virol. 77:1996;2001-2008.